Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd ( (AU:OSL) ) has provided an update.
OncoSil Medical Ltd reported record cash receipts for Q1 FY26, marking a 917% increase from the previous year, driven by increased sales and growing adoption of its OncoSil™ device. The company announced positive preliminary results from the PANCOSIL Phase 1-2 Study, indicating the safety and feasibility of their CT-guided percutaneous administration approach, which could lead to expanded treatment options for pancreatic cancer patients. Additionally, Dr. Thomas Duthy was appointed as Non-Executive Chairman, reinforcing the company’s strategic focus on advancing its position in the oncology device sector.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a medical device company specializing in localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The company focuses on developing and commercializing its OncoSil™ therapy, which is gaining traction in key markets across Europe.
Average Trading Volume: 26,857
Technical Sentiment Signal: Sell
Current Market Cap: A$28.24M
Learn more about OSL stock on TipRanks’ Stock Analysis page.